Insulin Estimation and Prediction: A Review of the Estimation and Prediction of Subcutaneous Insulin Pharmacokinetics in Closed-Loop Glucose Control

Patients affected by type 1 diabetes (T1D) suffer from lack of insulin secretion by the pancreas, due to the autoimmune destruction of the insulinproducing beta cells. This translates into elevated plasma glucose concentration with deleterious effects in the cardiovascular system, leading to serious...

Full description

Saved in:

Bibliographic Details
Published in:	IEEE control systems 2018-02, Vol.38 (1), p.47-66
Main Authors:	Bondia, Jorge, Romero-Vivo, Sergio, Ricarte, Beatriz, Diez, Jose Luis
Format:	Magazinearticle
Language:	eng
Subjects:	Biomedical monitoring Carbohydrates Cardiovascular system Diabetes Diabetes mellitus Glucose Hybrid systems Insulin Insulin pumps Medical treatment Pancreas Patient monitoring Pharmacokinetics Pharmacology Regulatory agencies Sugar
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Patients affected by type 1 diabetes (T1D) suffer from lack of insulin secretion by the pancreas, due to the autoimmune destruction of the insulinproducing beta cells. This translates into elevated plasma glucose concentration with deleterious effects in the cardiovascular system, leading to serious long-term complications. With the improvement of continuous glucose monitoring (CGM) technology, a significant amount of research has been focused in the last decade on the development of an artificial pancreas (AP), that is, a closed-loop glucose control system that automatically dispenses insulin. The AP is now closer to reality [1]. An AP system was first approved by the U.S. Food and Drug Administration (FDA) in 2016 [2]. The system still requires user intervention at mealtime, as currently done in openloop insulin pump therapy, to administer an insulin bolus based on carbohydrate counting (a hybrid closed-loop system).
ISSN:	1066-033X 1941-000X